Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early phase 2 trial of GCP-002 (EP-HMRG) fluorescence diagnosis in esophageal squamous cell carcinoma
jRCT2031240154Phase 2Completed
- Sponsor
- GORYO Chemical
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EP-HMRG in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by GORYO Chemical. Primary endpoint: Primary diagnostic performance of fluorescence imaging in target area. Started Sep 2024; status: completed.
02
Drugs
EP-HMRG
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2031240154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240154.